Loading...
•
Dec 31, 2021
MannKind Q4 2021 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2021.
Key Takeaways
MannKind Corporation reported a solid fourth quarter with Afrezza net revenue hitting a record $11.3 million, and the company ended the year with over $260 million in cash and investments. Total revenues were $12.5 million, with Afrezza net revenue contributing $11.3 million and collaborations and services revenue contributing $1.2 million. The net loss for the quarter was $28.1 million, or $0.11 per share.
Afrezza net revenue reached a record $11.3 million in Q4 2021, a 13% increase compared to Q4 2020.
Total revenues for Q4 2021 were $12.5 million, including $11.3 million from Afrezza and $1.2 million from collaborations and services.
The company had over $260 million in cash and investments at the end of 2021.
Net loss for Q4 2021 was $28.1 million, or $0.11 per share.
Revenue by Segment
Forward Guidance
MannKind is focused on commercial growth, pipeline advancement, and managing cash resources.
Positive Outlook
- Future commercial growth
- Pipeline advancement
- Ability to commercialize pharmaceutical products
- Solid cash position
- Focus on inhaled therapeutic products
Challenges Ahead
- Risks associated with product commercialization
- Risks associated with developing product candidates
- Risks associated with MannKind’s ability to manage its existing cash resources or raise additional cash resources
- Impact of the COVID-19 pandemic
- Stock price volatility
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...